Clinical trial
Altretamine and Etoposide in Treating Patients With HIV-Related Cancer
NCT00002936 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00002936 |
|---|---|
| Title | Altretamine and Etoposide in Treating Patients With HIV-Related Cancer |
| Official title | Hexamethylamine and VP-16 an Oral Regimin for HIV Malignancies: A Phase I/II Trial |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Sarcoma |
| Intervention type | Drug |
| Interventions | altretamine, etoposide |
| Start date | Jul 1, 1996 |
| Primary completion | Jan 1, 2007 |
| First posted | May 13, 2004 |
| Last update posted | Feb 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: